Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies

NCT01810926 is registered in ClinicalTrials.gov with Franco Locatelli as lead sponsor.

NCT NCT01810926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01810926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies
Lead sponsor
Franco Locatelli
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2011
Completion date
October 31, 2016
Enrollment
130 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease